PMID- 34884492
OWN - NLM
STAT- MEDLINE
DCOM- 20211217
LR  - 20230921
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 23
DP  - 2021 Nov 24
TI  - Host Factors in Dysregulation of the Gut Barrier Function during 
      Alcohol-Associated Liver Disease.
LID - 10.3390/ijms222312687 [doi]
LID - 12687
AB  - Chronic alcohol consumption and alcohol-associated liver disease (ALD) represent 
      a major public health problem worldwide. Only a minority of patients with an 
      alcohol-use disorder (AUD) develop severe forms of liver disease (e.g., 
      steatohepatitis and fibrosis) and finally progress to the more advanced stages of 
      ALD, such as severe alcohol-associated hepatitis and decompensated cirrhosis. 
      Emerging evidence suggests that gut barrier dysfunction is multifactorial, 
      implicating microbiota changes, alterations in the intestinal epithelium, and 
      immune dysfunction. This failing gut barrier ultimately allows microbial 
      antigens, microbes, and metabolites to translocate to the liver and into systemic 
      circulation. Subsequent activation of immune and inflammatory responses 
      contributes to liver disease progression. Here we review the literature about the 
      disturbance of the different host defense mechanisms linked to gut barrier 
      dysfunction, increased microbial translocation, and impairment of liver and 
      systemic inflammatory responses in the different stages of ALD.
FAU - Maccioni, Luca
AU  - Maccioni L
AD  - Laboratory of Hepato-Gastroenterology, Institute of Experimental and Clinical 
      Research, UCLouvain, Unversite Catholique de Louvain, 1200 Brussels, Belgium.
FAU - Leclercq, Isabelle A
AU  - Leclercq IA
AD  - Laboratory of Hepato-Gastroenterology, Institute of Experimental and Clinical 
      Research, UCLouvain, Unversite Catholique de Louvain, 1200 Brussels, Belgium.
FAU - Schnabl, Bernd
AU  - Schnabl B
AD  - Department of Medicine, University of California San Diego, La Jolla, CA 92093, 
      USA.
AD  - Department of Medicine, VA San Diego Healthcare System, San Diego, CA 92161, USA.
FAU - Starkel, Peter
AU  - Starkel P
AD  - Laboratory of Hepato-Gastroenterology, Institute of Experimental and Clinical 
      Research, UCLouvain, Unversite Catholique de Louvain, 1200 Brussels, Belgium.
AD  - Department of Hepato-Gastroenterology, Cliniques Universitaires Saint-Luc, 1200 
      Brussels, Belgium.
LA  - eng
GR  - P30 DK120515/DK/NIDDK NIH HHS/United States
GR  - R01 AA024726/AA/NIAAA NIH HHS/United States
GR  - R01 AA24726; P30 DK120515; P50 AA011999/NH/NIH HHS/United States
GR  - P50 AA011999/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20211124
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Animals
MH  - Dysbiosis/microbiology/*pathology
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Liver Diseases, Alcoholic/*complications/microbiology
PMC - PMC8657823
OTO - NOTNLM
OT  - chronic alcohol consumption
OT  - gut-liver axis
OT  - inflammation
OT  - intestinal barrier
OT  - intestinal immunity
COIS- The authors declare no conflict of interest.
EDAT- 2021/12/11 06:00
MHDA- 2021/12/18 06:00
PMCR- 2021/11/24
CRDT- 2021/12/10 01:03
PHST- 2021/10/25 00:00 [received]
PHST- 2021/11/18 00:00 [revised]
PHST- 2021/11/23 00:00 [accepted]
PHST- 2021/12/10 01:03 [entrez]
PHST- 2021/12/11 06:00 [pubmed]
PHST- 2021/12/18 06:00 [medline]
PHST- 2021/11/24 00:00 [pmc-release]
AID - ijms222312687 [pii]
AID - ijms-22-12687 [pii]
AID - 10.3390/ijms222312687 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Nov 24;22(23):12687. doi: 10.3390/ijms222312687.